tariquidar [Ligand Id: 11787] activity data from GtoPdb and ChEMBL

Click here for a description of the charts and data table

Please tell us if you are using this feature and what you think!

ChEMBL ligand: CHEMBL348475 (Tariquidar, XR-9576, XR9576)
  • ABCG2/ATP-binding cassette sub-family G member 2 in Human [ChEMBL: CHEMBL5393] [GtoPdb: 792] [UniProtKB: Q9UNQ0]
There should be some charts here, you may need to enable JavaScript!
  • ABCC1/Multidrug resistance-associated protein 1 in Human [ChEMBL: CHEMBL3004] [GtoPdb: 779] [UniProtKB: P33527]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
DB Assay description Assay Type Standard value Standard parameter Original value Original units Original parameter Reference
ABCG2/ATP-binding cassette sub-family G member 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5393] [GtoPdb: 792] [UniProtKB: Q9UNQ0]
ChEMBL Inhibition of ABCG2 in topotecan-cultured human MCF7 cells using Hoechst 33342 as substrate measured after 2 hrs by fluorescence assay B 5.21 pIC50 6223 nM IC50 Eur J Med Chem (2020) 191: 112133-112133 [PMID:32105979]
ChEMBL Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining B 5.82 pIC50 1500 nM IC50 Bioorg Med Chem (2011) 19: 2090-2102 [PMID:21354800]
ChEMBL Inhibition of ABCG2 in human mitoxantrone-resistant MCF7 cells by Hoechst 33342 assay B 5.84 pIC50 1445.44 nM IC50 Bioorg Med Chem (2008) 16: 8224-8236 [PMID:18678495]
ChEMBL Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining B 6.03 pIC50 940 nM IC50 Bioorg Med Chem (2011) 19: 2090-2102 [PMID:21354800]
ChEMBL Inhibition of ABCG2 overexpressed in human MCF7/Topo cells by flow cytometric-based mitoxantrone efflux assay B 6.04 pIC50 916 nM IC50 J Med Chem (2009) 52: 1190-1197 [PMID:19170519]
ChEMBL Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay B 6.07 pIC50 850 nM IC50 Bioorg Med Chem Lett (2010) 20: 180-183 [PMID:19932960]
ChEMBL Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining B 6.17 pIC50 680 nM IC50 Bioorg Med Chem Lett (2010) 20: 180-183 [PMID:19932960]
ChEMBL Inhibition of ABCG2 expressed in human MCF7/Topo cells by Hoechst microplate assay B 6.28 pIC50 526 nM IC50 Bioorg Med Chem Lett (2011) 21: 3654-3657 [PMID:21570282]
ChEMBL Inhibition of ABCG2 in human MCF7/Topo cells after 2 hrs by Hoechst 33342 microplate assay B 6.28 pIC50 526 nM IC50 ACS Med Chem Lett (2013) 4: 393-396 [PMID:24900683]
ChEMBL Inhibition of ABCG2 in human MCF7/Topo cells after 2 hrs by Hoechst 33342 staining based fluorescence assay B 6.28 pIC50 526 nM IC50 ACS Med Chem Lett (2018) 9: 854-859 [PMID:30128080]
ChEMBL Inhibition of ABCG2 in human MCF7/Topo cells by Hoechst 33342 assay B 6.28 pIC50 520 nM IC50 Eur J Med Chem (2016) 109: 124-133 [PMID:26774038]
ChEMBL Inhibition of sulfasalazine-stimulated BCRP ATP ase activity (unknown origin) B 6.74 pIC50 183.3 nM IC50 J Med Chem (2021) 64: 3677-3693 [PMID:33729781]
ChEMBL Inhibition of BCRP (unknown origin) B 7 pEC50 100 nM EC50 J Med Chem (2019) 62: 8578-8608 [PMID:31465686]
ChEMBL Activity at BCRP (unknown origin) expressed in MDCK cells using rhodamine 123 as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by fluorometric analysis B 8 pEC50 10 nM EC50 Bioorg Med Chem Lett (2013) 23: 1370-1374 [PMID:23374872]
ABCC1/Multidrug resistance-associated protein 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3004] [GtoPdb: 779] [UniProtKB: P33527]
ChEMBL Inhibition of NEM-GS-stimulated MRP1 ATPase activity (unknown origin) in presence of GSH B 4.62 pIC50 23780 nM IC50 J Med Chem (2021) 64: 3677-3693 [PMID:33729781]
ABCB1/P-glycoprotein 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4302] [GtoPdb: 768] [UniProtKB: P08183]
ChEMBL Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured after 24 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM) B 4.84 pIC50 14390 nM IC50 Bioorg Med Chem (2017) 25: 4194-4202 [PMID:28645831]
ChEMBL Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured after 12 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM) B 5.08 pIC50 8280 nM IC50 Bioorg Med Chem (2017) 25: 4194-4202 [PMID:28645831]
ChEMBL Reversal of human ABCB1-mediated multidrug resistance in HEK293/MDR19 cells assessed as effect on colchicine-induced cytotoxicity at 1 uM by measuring colchine IC50 after 72 hrs by CCK8 assay (Rvb = 97.58 +/- 17.62 uM) B 5.11 pIC50 7830 nM IC50 J Nat Prod (2020) 83: 1461-1472 [PMID:32347726]
ChEMBL Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 5 uM after 72 hrs by MTT assay (Rvb = 398.34 +/- 0.58 uM) B 5.28 pIC50 5240 nM IC50 Eur J Med Chem (2019) 161: 364-377 [PMID:30384042]
ChEMBL Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured after 6 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM) B 5.3 pIC50 4970 nM IC50 Bioorg Med Chem (2017) 25: 4194-4202 [PMID:28645831]
ChEMBL Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 398.34 +/- 0.58 uM) B 5.35 pIC50 4460 nM IC50 Eur J Med Chem (2019) 161: 364-377 [PMID:30384042]
ChEMBL Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured immediately by MTT assay (Rvb = 51.34 +/- 5.1 uM) B 5.52 pIC50 3020 nM IC50 Bioorg Med Chem (2017) 25: 4194-4202 [PMID:28645831]
ChEMBL Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 at 5 uM measured after 48 hrs by MTT assay (Rvb = 43.75 to 96.91 uM) B 5.71 pIC50 1970 nM IC50 Bioorg Med Chem (2017) 25: 4194-4202 [PMID:28645831]
ChEMBL Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 measured after 48 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM) B 5.8 pIC50 1600 nM IC50 Bioorg Med Chem (2017) 25: 4194-4202 [PMID:28645831]
ChEMBL Inhibition of sulfasalazine-stimulated ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay B 5.93 pIC50 >=1180 nM IC50 Eur J Med Chem (2020) 191: 112133-112133 [PMID:32105979]
ChEMBL Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by measuring adriamycin IC50 after 48 hrs by MTT assay B 6.34 pIC50 460 nM IC50 J Med Chem (2021) 64: 6179-6197 [PMID:33938746]
ChEMBL Inhibition of ABCB1 in human KB-V1 cells using calcein-AM as substrate measured after 10 mins by fluorescence assay B 6.45 pIC50 356 nM IC50 Eur J Med Chem (2020) 191: 112133-112133 [PMID:32105979]
ChEMBL Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM) B 6.62 pIC50 240 nM IC50 J Nat Prod (2016) 79: 2135-2142 [PMID:27504669]
ChEMBL Inhibition of ABCB1 in human KBV1 cells after 10 mins by Calcein-AM microplate assay B 6.65 pIC50 223 nM IC50 ACS Med Chem Lett (2013) 4: 393-396 [PMID:24900683]
ChEMBL Inhibition of ABCB1 expressed in Kb-V1 cells after 10 mins by calcein-AM assay B 6.65 pIC50 223 nM IC50 Bioorg Med Chem Lett (2011) 21: 3654-3657 [PMID:21570282]
ChEMBL Inhibition of ABCB1 overexpressed in human KBv1 cells by flow cytometric-based calcein-AM efflux assay B 6.65 pIC50 223 nM IC50 J Med Chem (2009) 52: 1190-1197 [PMID:19170519]
ChEMBL Inhibition of ABCB1 in human KBV1 cells assessed as inhibition of calcein-AM efflux B 6.66 pIC50 220 nM IC50 Eur J Med Chem (2016) 109: 124-133 [PMID:26774038]
ChEMBL Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry B 6.68 pIC50 210 nM IC50 Bioorg Med Chem (2011) 19: 2090-2102 [PMID:21354800]
ChEMBL Inhibition of human Pgp in A2780 cells after 30 mins by Hoechst 33342 assay B 6.9 pIC50 125.89 nM IC50 Bioorg Med Chem (2008) 16: 2448-2462 [PMID:18083034]
ChEMBL Inhibition of P-glycoprotein-mediated multidrug resistance in adriamycin-resistant human A2780/ADR cells by calcein AM assay B 7.11 pIC50 78 nM IC50 Bioorg Med Chem (2009) 17: 2524-2535 [PMID:19250834]
ChEMBL Inhibition of P-gp in human adriamycin-resistant A2780 cells by Hoechst 33342 assay B 7.14 pIC50 72.44 nM IC50 Bioorg Med Chem (2008) 16: 8224-8236 [PMID:18678495]
ChEMBL Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 5.07 +/- 0.19 uM) B 7.15 pIC50 70 nM IC50 J Nat Prod (2016) 79: 2135-2142 [PMID:27504669]
ChEMBL Inhibition of Pgp by daunorubicin accumulation assay B 7.42 pIC50 38.02 nM IC50 Bioorg Med Chem (2008) 16: 2448-2462 [PMID:18083034]
ChEMBL Inhibition of Pgp by daunorubicin accumulation assay B 7.42 pIC50 38 nM IC50 Bioorg Med Chem (2008) 16: 2448-2462 [PMID:18083034]
ChEMBL Inhibition of P-glycoprotein-mediated daunorubicin efflux from human CCRF-CEM/VCR1000 cells after 240 secs by FACS flow cytometric analysis B 7.48 pIC50 33.11 nM IC50 J Med Chem (2012) 55: 3261-3273 [PMID:22452412]
ChEMBL Inhibition of paclitaxel stimulated- P-gp ATPase activity (unknown origin) B 7.49 pIC50 32.7 nM IC50 J Med Chem (2021) 64: 3677-3693 [PMID:33729781]
ChEMBL Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM) B 7.6 pIC50 24.97 nM IC50 J Nat Prod (2016) 79: 2135-2142 [PMID:27504669]
ChEMBL Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1000 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM) B 7.61 pIC50 24.77 nM IC50 J Nat Prod (2016) 79: 2135-2142 [PMID:27504669]
ChEMBL Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM) B 7.73 pIC50 18.51 nM IC50 J Nat Prod (2016) 79: 2135-2142 [PMID:27504669]
ChEMBL Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 487.57 +/- 30.54 nM) B 8.04 pIC50 9.05 nM IC50 J Nat Prod (2016) 79: 2135-2142 [PMID:27504669]
ChEMBL Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 5 uM measured after 72 hrs by MTT assay B 8.12 pIC50 7.57 nM IC50 Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797]
ChEMBL Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM measured after 72 hrs by MTT assay B 8.35 pIC50 4.46 nM IC50 Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797]
ChEMBL Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by MTT assay B 8.48 pIC50 3.34 nM IC50 Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797]
ChEMBL Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 5 uM measured after 72 hrs by MTT assay B 8.49 pIC50 3.26 nM IC50 Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797]
ChEMBL Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM measured after 72 hrs by MTT assay B 8.69 pIC50 2.05 nM IC50 Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797]
ChEMBL Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by MTT assay B 9.15 pIC50 0.71 nM IC50 Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797]
ChEMBL Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 277.68 +/- 56.61 nM) B 9.18 pIC50 0.66 nM IC50 J Nat Prod (2016) 79: 2135-2142 [PMID:27504669]
ChEMBL Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM measured after 72 hrs by MTT assay B 9.59 pIC50 0.26 nM IC50 Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797]
ChEMBL Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM measured after 72 hrs by MTT assay B 9.66 pIC50 0.22 nM IC50 Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797]
ChEMBL Activation of ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay B 6.68 pEC50 211 nM EC50 Eur J Med Chem (2020) 191: 112133-112133 [PMID:32105979]
ChEMBL Reversal of P-gp-mediated multidrug resistance to vinblastine in human CEM/VLB500 cells after 3 days by resazurin assay B 7.17 pEC50 68 nM EC50 Bioorg Med Chem (2007) 15: 3854-3868 [PMID:17399990]
ChEMBL Activity at MDR1 (unknown origin) expressed in MDCK cells using calcein AM as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by fluorometric analysis B 7.36 pEC50 44 nM EC50 Bioorg Med Chem Lett (2013) 23: 1370-1374 [PMID:23374872]
ChEMBL Inhibition of P-glycoprotein (unknown origin) expressed in MDCK cells assessed as reduction of calcein-AM transport after 30 mins by fluorescence assay B 7.36 pEC50 44 nM EC50 Eur J Med Chem (2014) 76: 558-566 [PMID:24607999]
ChEMBL Inhibition of P-gp (unknown origin) expressed in MES-SA/DX5 cells assessed as cell growth inhibition after 3 days in presence of 200 nM paclitaxel by MTT assay B 7.8 pEC50 16 nM EC50 J Med Chem (2021) 64: 3677-3693 [PMID:33729781]
P-glycoprotein 1 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3467] [UniProtKB: P06795]
ChEMBL Inhibition of mouse Pgp in EMT6/AR1.0 cells after 1 hr by daunorubicin accumulation assay B 7.19 pIC50 64.57 nM IC50 Bioorg Med Chem (2008) 16: 2448-2462 [PMID:18083034]
ChEMBL Inhibition of mouse Pgp in EMT6/AR1.0 cells after 1 hr by daunorubicin accumulation assay B 7.19 pIC50 64 nM IC50 Bioorg Med Chem (2008) 16: 2448-2462 [PMID:18083034]

ChEMBL data shown on this page come from version 33:

Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]